• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Real-world data backs Insulet Omnipod 5 in children

March 7, 2025 By Sean Whooley

Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]
A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young people.

Omnipod 5, Insulet’s latest-generation automated insulin delivery (AID) system, is a small, discreet, tubeless, wearable patch pump. It features SmartAdjust technology that uses CGM readings to predict where glucose will be 60 minutes into the future. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.

The real-world study aimed to evaluate Omnipod 5’s effectiveness in HbA1c, time-in-range (TIR), hypoglycemia frequency and sensor glucose variability. It lasted over three and six months in children and young people with type 1 diabetes at two NHS-funded pediatric diabetes centers in North West England. Findings were published last month in Diabetes Technology & Therapeutics.

Children under 18 years old started on Omnipod 5 therapy (using the Dexcom G6 CGM) between August 2023 and January 2024 in the study. Investigators collected sensor glucose metrics and HbA1c within three months before pump initiation. They then compared the data at three and six months post-initiation.

The study included a total of 144 children, with 46% males and a mean age of 7.1 years. It had a predominantly White cohort (80%) with diabetes duration averaging 4.4 years. Before Omnipod 5, 54% used multiple daily injections, 41% a nonintegrated pump and 5% another AID system.

At three and six months, subjects saw significant improvements in HbA1c (7.7% to 7.1% at three months and 7.2% at six months). TIR improved from 53.3% at baseline to 67.4% at three months and 68.8% at six months.

Investigators concluded:

“These findings highlight the Omnipod 5 system’s safety and effectiveness in improving glycemic control for children and young people (CYP) with type 1 diabetes in a real-world NHS setting. Further research is needed to explore the long-term benefits and cost-effectiveness of this tubeless HCL system in routine clinical care.”

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Insulet

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS